Please assess the completion status of the following clinical trial:

Trial Title: Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Preexisting type 2 diabetes mellitus requiring medical treatment or~* overt diabetes diagnosed prior to 20 weeks of gestation using either Hemoglobin A1c (HBA1C) ≥ 6.5 or fasting glucose ≥126 mg/dl or random blood glucose ≥ 200 mg/dl or two step method ( 50g glucose challenge test (GCT) \>135 mg/dl followed by 100 GCT with at least 2 values above thresholds: Fasting Blood Glucose (FBG) \>90, 1 hr \>180, 2 hr \> 155, 3 hr \> 140 mg/dl).~* Gestational age ≤20 weeks~* Willing to start insulin therapy or to continue insulin treatment during pregnancy~* Singleton or twin pregnancy~Exclusion Criteria:~* Known allergy/prior adverse reaction to NPH/detemir~* Patients \<18y~* Known major fetal anomalies~* Diabetic nephropathy (Creatinine (Cr)≥1.5)~* Diabetic proliferative retinopathy~* Patients with Type 1 diabetes or gestational diabetes

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neutral Protamine Hagedorn (NPH) (Type: ACTIVE_COMPARATOR): NPH will peak between 4-12 hours after injection with a duration of action around 14 hours
- Detemir (Type: ACTIVE_COMPARATOR): Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)

Based on this trial design, predict the completion outcome and termination type (if applicable).